Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

Akane Inoue-Yamauchi; Paul S. Jeng; Kwanghee Kim; Hui-Chen Chen; Song Han; Yogesh Tengarai Ganesan; Kota Ishizawa; Sylvia Jebiwott; Yiyu Dong; Maria C. Pietanza; Matthew D. Hellmann; Mark G. Kris; James J. Hsieh; Emily H. Cheng

doi:10.1038/ncomms16078

Nature Communications (Jul 2017)

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

Akane Inoue-Yamauchi,
Paul S. Jeng,
Kwanghee Kim,
Hui-Chen Chen,
Song Han,
Yogesh Tengarai Ganesan,
Kota Ishizawa,
Sylvia Jebiwott,
Yiyu Dong,
Maria C. Pietanza,
Matthew D. Hellmann,
Mark G. Kris,
James J. Hsieh,
Emily H. Cheng

Affiliations

Akane Inoue-Yamauchi: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Paul S. Jeng: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Kwanghee Kim: Department of Surgery, Memorial Sloan Kettering Cancer Center
Hui-Chen Chen: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Song Han: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Yogesh Tengarai Ganesan: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Kota Ishizawa: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Sylvia Jebiwott: Department of Surgery, Memorial Sloan Kettering Cancer Center
Yiyu Dong: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
Maria C. Pietanza: Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Matthew D. Hellmann: Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Mark G. Kris: Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
James J. Hsieh: Department of Medicine, Molecular Oncology, Siteman Cancer Center, Washington University
Emily H. Cheng: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center

DOI: https://doi.org/10.1038/ncomms16078
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 14

Abstract

Read online

Small cell lung cancer cells (SCLC) are differentially sensitive to inhibitors of the BCL-2 family. Here the authors analyse the response to BH3 mimetics in SCLC, delineate patterns of expression of apoptotic proteins correlated with differential sensitivities and demonstrate a synergistic anti-tumour activity between ABT-199 and anthracyclines or CDK9 inhibitors.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal